Polylactide-cyclosporin A nanoparticles for targeted immunosuppression

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Immunology

Background:

• Polymeric nanoparticles (NPs) are advanced drug delivery systems offering improved efficacy and reduced toxicity.
• Cyclosporine A (CsA) is an immunosuppressive drug crucial for preventing transplant rejection and treating autoimmune diseases.
• Targeted delivery of CsA to immune cells, particularly in lymph nodes, is essential for optimizing its therapeutic effect and minimizing systemic side effects.

Purpose of the Study:

• To develop a novel method for preparing polylactide-cyclosporine A (PLA-CsA) nanoparticles (CsA-NPs) using CsA-initiated ring-opening polymerization.
• To characterize the physicochemical properties and drug release profile of the synthesized CsA-NPs.
• To evaluate the in vitro and in vivo efficacy of CsA-NPs in suppressing T-cell proliferation and inflammatory responses, with a focus on targeted delivery to lymph nodes via dendritic cells (DCs).

Main Methods:

• Synthesis of CsA-NPs via CsA-initiated ring-opening polymerization of lactide (LA) followed by nanoprecipitation.
• Characterization of CsA-NPs size, size distribution, and CsA release kinetics.
• In vitro evaluation of CsA-NPs' efficacy in suppressing T-cell proliferation and cytokine production using T-cell assays.
• In vivo studies involving coupling CsA-NPs with dendritic cells (DCs) for targeted delivery to lymph nodes and assessment of T-cell priming reduction.

Main Results:

• CsA-NPs were successfully prepared with sub-100 nm sizes and narrow particle size distributions.
• Sustained release of CsA from CsA-NPs was observed without an initial burst-release effect.
• Both free CsA and CsA-NPs demonstrated dose-dependent suppression of T-cell proliferation and inflammatory cytokine production, with IC(50) values of 27.5 ng/ml for CsA and 72.0 ng/ml for CsA-NPs.
• DCs coupled with CsA-NPs effectively delivered CsA to lymph nodes, significantly reducing alloreactive T-cell proliferation and priming without systemic release.

Conclusions:

• The developed CsA-initiated polymerization strategy provides an effective method for creating well-defined CsA-loaded polymeric nanoparticles.
• CsA-NPs exhibit favorable drug release characteristics and potent immunosuppressive activity in vitro.
• Targeted delivery of CsA-NPs via DCs to lymph nodes demonstrates significant potential for enhancing immunosuppression efficacy and reducing systemic toxicity in vivo.
• This novel nanoparticulate drug delivery system offers a promising platform for future targeted delivery of immunosuppressive agents.